drugset
drugset / Trial / NCT04586270

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

NCT04586270 ↗

Phase 1 Terminated 47 enrolled Taiho Oncology, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.

Timeline

Start
2020-10-15
Primary completion
2024-11-14
Completion
2024-11-14

Outcome

Outcome not reported

Stopped (Business): “Taiho Oncology as the sponsor of study TAS0612-101, has made a strategic decision to terminate the TAS0612-101 study, taking into consideration the safety profile of TAS0612 and the absence of encouraging anti-tumor activity.”

Drugs

EvaluationDrugModalityDoseRoute
Subject TAS0612 Small molecule — Oral

Indications

No indication recorded.